Navigation Links
New Biopharmaceutical Company to Accelerate Delivery of Vaccines and Protein Therapeutics
Date:4/25/2011

BRYAN/COLLEGE STATION, Texas, April 25, 2011 /PRNewswire/ -- Caliber Biotherapeutics, a fully-integrated biopharmaceutical company, announced the opening of the world's largest plant-made pharmaceutical manufacturing facility in Bryan, Texas, with the capability of producing 10-100 million doses of infectious vaccines per month, and hundreds of thousands of doses of protein biotherapeutics such as monoclonal antibodies.

In addition to its plant-based facility, Caliber will also develop a proprietary product pipeline for cancer and infectious diseases utilizing cell- and microbial-based production systems. The end result will be new, more effective and affordable vaccines and biotherapeutics for patients – delivered in a time frame in which they are needed.

Led by physician-scientist and biodefense expert, Brett Giroir, M.D., and Barry Holtz, Ph.D., an internationally recognized pioneer in plant-made pharmaceuticals, Caliber Biotherapeutics represents a fundamentally different approach to vaccine and drug development.

"With plant-based systems, we have an unprecedented level of flexibility and scalability," said Dr. Holtz, Caliber's Chief Scientific Officer. "This enables simultaneous production of multiple proteins and rapid change-overs from one product to another in order to meet patients' needs and respond to emerging infectious diseases and bioterror threats."

"The Caliber platform is designed to be uniquely agile and responsive, enabling us to accelerate development of products with improved efficacy, reduced cost and enhanced safety," said Dr. Giroir, Chief Medical Officer.  "Our goal is to make a rapid, meaningful impact on patients with unmet medical needs, both in the United States as well as in lesser developed countries with profound public health challenges."

In the coming months, Caliber will be announcing new major strategic alliances and its priorities for product development.

About Caliber Biotherapeutics

Caliber Biotherapeutics is a fully integrated biopharmaceutical company dedicated to creating greater and faster access to protein therapeutics and vaccines for cancer, infectious and orphan diseases. The company leverages highly agile, modular production technology and plant-, cell-, and microbial-based systems capable of accelerating delivery of novel treatments with increased efficacy and safety

Headquartered in Bryan / College Station, Texas, Caliber Biotherapeutics has assembled a world-class team of experts and established the world's largest plant-made pharmaceuticals facility that uniquely responds to changing demands and scale requirements. For more information, please visit the company's website at www.caliberbio.com


'/>"/>
SOURCE Caliber Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
2. Reportlinker Adds Top 200 Biopharmaceuticals Industry Report (Global)
3. New Survey Emphasizes Value of Biopharmaceutical Company Engagement With Healthcare Providers
4. Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited
5. Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
6. Cytel Hires Biopharmaceutical Development Veteran Jim Baker to Support Expansion of its Clinical Research Offerings
7. Lilly CEO Calls for Biopharmaceutical Industry Changes and Policies That Encourage Medical Innovation
8. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
10. Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundations 2011 Spring Clinical Meetings
11. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 True Health ... brings leading-edge laboratory services and management expertise to ... , allowing more doctors and patients to ... management solutions. Logo - http://photos.prnewswire.com/prnh/20161208/447162LOGO ... Hospital systems, under pressure to contain costs, have ...
(Date:12/8/2016)... Research and Markets has announced the addition of the ... ... The global chromatography market to grow at a CAGR of 5.42% during ... prepared based on an in-depth market analysis with inputs from industry experts. ... coming years. The report also includes a discussion of the key vendors ...
(Date:12/8/2016)... , December 8, 2016 ... "Sugar-Based Excipients Market by Product (Actual Sugars, Sugar ... (Filler & Diluent, Tonicity Agents), Formulation (Oral, Topical, ... MarketsandMarkets, the market has witnessed healthy growth during ... at a CAGR of 4.3% between 2016 and ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 08, 2016 , ... ZyDoc , a New York-based ... Data Capture Methods for Input to Electronic Health Records: A Comparative Usability Study” ... comparative usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s MediSapien™ ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s leading digital and ... with Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media Group ... said, “CURE Media Group is honored to team up with Upstage Lung Cancer in ...
(Date:12/8/2016)... ... 2016 , ... Premier Fitness Camp (PFC) and The Chopra Center for Wellbeing ... wellness program, at their world headquarters of Omni La Costa Resort & Spa in ... anyone seeking weight loss, personal development, a healthy lifestyle, or mental and physical healing. ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development solutions for drugs, biologics and consumer health products, today announced that it ... up in 2006 as a non-profit organization to unite pharmaceutical and healthcare companies ...
(Date:12/8/2016)... ... ... California Senate Bill (SB) 863, signed into law in 2012, may have ... according to CompScope™ Medical Benchmarks for California, 17th Edition , a study by ... payments per claim in California decreased 4 percent in 2013 and then 3 percent ...
Breaking Medicine News(10 mins):